|
|
 |
|
Viewing report
|
|
|
|
Codeveloping Targeted Therapies and Diagnostics: What's in it for Me?
Decision Resources, Inc, Nov 2006, Pages: 26
Introduction
Drug-test(RxDx) companion products pair a drug and a diagnostic test that can tell physicians which patients will benefit most from treatment with the drug. This report examines whether it is appropriate to ask pharmaceutical, biotech and diagnostics companies to develop these products when they may question what benefi t they will receive from such development; after all, these companies are already developing good drugs and good tests to treat many people. We examine the FDA’s efforts to encourage development of RxDx products, possible incentives to both drug and diagnostics companies, the companies that we believe are currently suited to find success and what factors will likely play into this success.
Get the Answers You Need to Shape Your Strategy
The benefi ts of RxDx companion products could be very high for individual patients and society. However, decisions in the drug and diagnostics industries are based on economics. What will development of such tests cost? How will companies know when it makes financial sense to develop them?
Technology now exists to exploit the information in human genes to make better medicines that treat not just large patient populations but also individual patients through personalized medicine. How can drug and diagnostics companies best benefit from this new knowledge? How can they strike a balance between public benefit and company profit? Try as the FDA might to encourage the codevelopment of RxDx products, a lack of obvious economic benefi t to the pharmaceutical and diagnostics industries has caused these industries to drag their feet in the development of personalized medicine and RxDx products specifically. What incentives are being considering to encourage development of these products? Can the cost of development be decreased? Should pricing/reimbursement for RxDx products be increased? What other incentives are reasonable?
The goal of incentives to encourage development of RxDx products must be to balance the needs of many stakeholders—including patients, doctors, and payers as well as diagnostics and pharmaceutical/biotech companies. What monetary or legislative incentives can benefit most stakeholders?
Aside from economic considerations, what factors could stand in the way of development of these tests?
Scope
Key codevelopment concepts: April 2005 FDA paper “Drug-Diagnostic Co-Development Concept Paper,” and ownership and role of biomarkers.
Benefits and incentives for stakeholders: detailed coverage of four incentive possibilities.
Case study: Herceptin, HER-2 tests, and a pharmaceutical company executive’s perspective on the value of RxDx.
Outlook: DxRx partnering challenges, parallel and nonparallel RxDx partnerships, and companies to watch.
|
|
|
|
